Downloaded from molecularcasestudies.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press

Title: Neonatal Mellitus Due to a Novel Variant in the INS

Authors: Sarah E. Laurenzano1, Cory McFall2, Linda Nguyen3, Dipal Savla3, Nicole G. Coufal2, Meredith S. Wright4, Mari Tokita4, David Dimmock4, Stephen F. Kingsmore4, and Ron S. Newfield1

1. Division of Pediatric , Department of Pediatrics, UCSD 2. Division of Pediatric Intensive Care Medicine, Department of Pediatrics, UCSD 3. Department of Pediatrics, UCSD 4. Rady Children's Institute for Genomic Medicine

Corresponding author: Ron S. Newfield, [email protected]

Running title: INS-associated neonatal diabetes mellitus

Abstract: Neonatal diabetes mellitus (NDM) is a rare condition that presents with diabetes in the first few months of life. The treatment of NDM may differ depending on the genetic etiology, with numerous studies showing benefit of therapy in cases caused by in KCNJ11 or ABCC8. Mutations in the gene (INS) have also been identified as causes of NDM; these cases are generally best treated with insulin alone. We report a case of a female born small for gestational age (SGA) at late preterm diagnosed with NDM at 7 weeks of life who was found by rapid whole genome sequencing to harbor a novel de novo c.26C>G (p.Pro9Arg) variant in the INS gene. She presented with diabetic which responded to insulin therapy. She did not respond to empiric trial of sulfonylurea therapy early in her hospital course, and it was discontinued once a genetic diagnosis was made. Early genetic evaluation in patients presenting with NDM is essential to optimize therapeutic decision-making.

Introduction: Neonatal diabetes mellitus (NDM) is a rare disorder that is defined by the onset of diabetes before age 6 months. Its incidence has been estimated at 1 in every 90,000-400,000 births (Iafusco et al 2012, Polak and Cave 2007). typically present with small size for gestational age (SGA), , failure to thrive, and with or without ketonuria or ketoacidosis. NDM can be either permanent or transient, and is likely to have an underlying genetic cause. The most common genetic etiologies of NDM in children born to non- consanguineous parents include mutations in KCNJ11 or ABCC8, the encoding the ATP-sensitive channel subunits Kir6.2 and SUR1, respectively; mutations involving the insulin (INS) gene; or abnormalities of 6q24 (De Franco et al 2015). Both autosomal recessive and autosomal dominant INS mutations have been described. Patients with defects in KCNJ11 or ABCC8 can often be managed well with sulfonylurea therapy (Babenko et al 2006, Pearson et al 2006). In cases involving other genetic mutations, insulin remains the mainstay of treatment. Here, we present a case of NDM caused by a de novo variant in the INS gene that highlights the utility of rapid whole genome sequencing in the clinical care of NDM. Downloaded from molecularcasestudies.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press

Case presentation: The patient is a female born at 36 weeks and 5 days gestation via Cesarean section because of placenta previa. The history was notable for classification of the infant as SGA by weight (birth weight of 2.01 kg, <1st %ile), and for report of enlarged kidneys on prenatal ultrasound. The postnatal history included a four-day NICU stay, with initial respiratory distress (resolved by discharge) and sepsis evaluation; note was also made of transient hyperglycemia presumed due to an exaggerated stress response which also resolved. In the outpatient setting, she was followed by her pediatrician for poor weight gain. She subsequently presented at the age of 7 weeks to an urgent care facility with tachypnea and a single episode of emesis. She was lethargic, tachycardic, dehydrated and in obvious respiratory distress. She was transferred to the pediatric emergency department for further care.

On arrival to our facility, the patient was again noted to be in respiratory distress, and her weight was again noted to be low (2.9 kg, <1st %ile for age). Laboratory studies showed a high anion gap of 22 mmol/L (reference range 5-20 mmol/L), metabolic acidosis (venous pH 7.096 [reference range 7.31-7.41], serum bicarbonate 6 mmol/L [reference range 18-27 mmol/L]), and profound hyperglycemia (initial serum 734 mg/dL [40.7 mmol/L], reference range 60- 110 mg/dL [3.3-6.1 mmol/L]). Isotonic fluid resuscitation was initiated with a total of 30 mL/kg of normal saline, and once serum blood glucose decreased below 600 mg/dL (33.3 mmol/L), a regular insulin infusion was begun at 0.05 units/kg/hr and soon after was increased to 0.1 units/kg/hr. The infant was admitted to the pediatric intensive care unit (PICU).

During the early portion of her PICU stay, blood glucose was monitored hourly and venous blood gas every two hours per protocol. Maintenance IV fluids were provided, with the addition of dextrose as appropriate with decreasing blood glucose. Ketoacidosis was deemed resolved within approximately 8 hours of admission, at which time feeding with breastmilk was allowed every three hours and subcutaneous insulin started. Initial regimen included low doses of glargine insulin and correctional dilute lispro insulin, the doses of which required frequent adjustment due to widely variable blood glucose values. Additional laboratory results from PICU stay included a hemoglobin A1c (HbA1c) of 6.3% (normal range 4.2-5.6%), very low C- (0.16 ng/mL, reference range 0.8-3.1 ng/mL) and low insulin level (1 mU/mL, reference range <17 mU/mL) which were inappropriately low for her hyperglycemic state, and negative insulin autoantibody (titer <0.4 U/mL). She was nominated for rapid whole genome sequencing (WGS) by our facility’s genomics institute while in the PICU on hospital day 5. She was able to be transferred out of the PICU by hospital day 6, and sample for WGS was collected that day.

Over the next few days, she continued to have widely variable blood glucose levels despite adjustments in dosing and timing of both glargine and dilute lispro insulin. With the knowledge that the majority of neonatal diabetes is caused by mutations in either ABCC8 or KCNJ11 that may be sulfonylurea-responsive, she was empirically started on twice-daily glyburide on day 7 of admission, which did not improve her hyperglycemia. On hospital day 8, genomic test results Downloaded from molecularcasestudies.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press

were available and showed a de novo heterozygous c.26C>G (p.Pro9Arg) variant in the INS gene (Table 1).

Table 1: Variant table Gene Chromosome HGVS HGVS Variant Predicted dbSNP/ Genotype ClinVarID DNA Protein Type Effect dbVar (heterozygous/ Reference Reference (substitution ID homozygous) , deletion, etc.) INS 11:2182176 c.26C>G p.Pro9Arg Missense Likely None Heterozygous SCV000898466 (NM_001185 pathogenic .1 098.1)

The p.Pro9Arg variant in INS, which has not been previously reported in the literature, is absent from the Exome Aggregation Consortium (ExAC) and genome aggregation (gnomAD) population databases. It involves a highly conserved amino acid (phyloP-Vertebrate: 3.35) and is predicted by multiple in silico tools to have a deleterious effect on protein function (MutationTaster: 0.991; SIFT: 0.006; Polyphen-2: 0.917). Analysis of the parental samples was negative for the c.26C>G (p.Pro9Arg) variant, indicating that it likely occurred as a de novo event in the patient. Therefore, the variant was classified as likely pathogenic. Glyburide was stopped within 36 hours after it was started based on the molecular diagnosis which indicated that sulfonylurea therapy would not be an effective adjunct.

In an effort to lessen glycemic variability and decrease the frequency of correctional dilute lispro insulin injections in an infant with multiple daily feeds, intermediate-acting insulin (NPH) was added and was discontinued, allowing the family to give lispro correctional injections less frequently. With dose titration over the next few days, blood glucose values were generally within acceptable range although some variability continued. She was able to be discharged on hospital day 12 on a regimen of NPH 1.5 units every 8 hours (1.55 units/kg/day for admission weight of 2.9 kg) and dilute lispro given for hyperglycemia as needed. Recognizing her increased risk for and glycemic variability due to her very young age and small size, we applied for a continuous glucose sensor (DexCom) during her hospital stay, which the family received within 2 weeks of hospital discharge. Family remained in close communication with the endocrinology team following hospital discharge for review of blood glucose values and insulin adjustments as appropriate. At follow-up at age 5 months, her HbA1c was 6.8% and weight had improved (weight for length at the 93rd %ile). Her regimen included twice-daily NPH insulin and twice-daily short-acting insulin (total of 0.46 units/kg/day) for carbohydrate coverage, with correctional insulin given in between those times as needed. At follow-up at age 9 months, her HbA1c was 7% and weight for length was at the 97th %ile. Her regimen was adjusted to discontinue NPH insulin and reintroduce once-daily insulin glargine along with short-acting insulin with all meals in a typical basal-bolus regimen (total of 0.77 units/kg/day).

Downloaded from molecularcasestudies.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press

Discussion: There is significant genetic heterogeneity in NDM, an entity that may be transient or permanent. In permanent neonatal diabetes (PNDM), the most common genetic mutations seen are in KCNJ11 and ABCC8, accounting for close to 50% of PNDM; INS gene mutations account for approximately 20% of PNDM, with mutations in other genes (such as GCK and PDX1) occurring less commonly (De León et al 2008). Both missense and loss-of-function variants in the INS gene have been described in individuals with PNDM (Liu et al 2015, Edghill et al 2008), with different types affecting different steps in insulin and function but all producing the phenotype of PNDM. The INS gene is translated into the precursor preproinsulin, which undergoes removal of its signal peptide to generate , after which further intracellular modifications including excision of C-peptide result in the mature form of insulin (Støy 2014). The novel p.Pro9Arg missense variant detected in our patient occurs in the signal peptide of the preproinsulin molecule, in an amino acid residue that is highly conserved.

While it could be hypothesized that the p.Pro9Arg variant disrupts insulin biosynthesis very early in the process, given the heterozygous nature of the mutation in this case, it is difficult to attribute development of overt, early-onset diabetes to insulin haploinsufficiency alone. Indeed, the molecular mechanisms underlying the development of PNDM in the setting of heterozygous INS mutations are not yet completely understood. Increased endoplasmic reticulum (ER) stress, with or without increased beta-cell , have been implicated (Oyadomari et al 2002, Balboa et al 2018). Recently, Balboa et al (2018) reported that iPSC-derived INS-mutant beta- like cells transplanted into mice increased ER stress, led to defective beta-cell mass expansion, and reduced insulin secretion. Liu et al (2011, 2015), in reviewing the diversity of the MIDY (Mutant INS-gene induced Diabetes of Youth) phenotype, describe the hypothesis of “gain-of- toxic-function” which is felt to be heavily implicated in the development of diabetes and which may be initiated by abnormal interactions between mutant and wild-type proinsulin molecules in the ER of beta cells.

Beyond providing information useful in understanding the pathogenesis of NDM in a case such as this, results of rapid genetic sequencing can be key in guiding management. In particular, it is well-known that NDM resulting from mutations in KCNJ11 and ABCC8 may respond well to sulfonylurea (SU) therapy. In general, it is felt that SU therapy is ineffective in cases of NDM due to INS gene mutations. In our case, SU therapy was empirically started while genetic testing results were pending. When these became available in the span of just two days, therapy was able to be appropriately tailored to the patient as it was evident that SU therapy would be ineffective based on the mechanism of disease. Moreover, although empiric therapy while awaiting genetic results is not uncommon, one case of emerging after addition of SU therapy in a patient with transient NDM due to a mutation in the region of INS has been described (Yildiz et al 2018). Although adverse effects with adjunctive SU Downloaded from molecularcasestudies.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press

therapy have not been commonly described, and while there may be significant genetic and clinical differences between patients with transient or permanent NDM, we feel that whenever possible it is important to prioritize ancillary genetic testing that may substantially impact management. Although other testing methods (e.g., targeted panel testing, whole exome sequencing) would also have provided an accurate diagnosis in this case, whole genome sequencing performed at our facility has a shorter turnaround time than most commercially available gene panel and exome sequencing tests. In fragile patients requiring intensive care, rapid diagnosis is crucial for timely, specific treatment which results in improved outcomes and decreased length of stay (Farnaes et al 2018).

A clinical feature of interest in this case was the diagnosis of bilateral kidney enlargement made on prenatal ultrasound. Her postnatal course has been notable for ultrasound during admission for DKA showing right kidney length of 5.5 cm and left kidney length 6.2 cm (both high-normal in size [Konuş et al 1998]) as well as moderate left hydronephrosis, SFU (Society for Fetal Urology) Grade 3. Nephromegaly and/or hydronephrosis are not commonly described in individuals with neonatal diabetes in the available literature; we speculate that this could be related to renal hyperfiltration due to hyperglycemia and in utero.

An additional clinical feature worth noting in this case includes the HbA1c of 6.3% at diagnosis; alternative estimates of glycemic control, such as or glycated albumin, were not measured in our patient. It has been described (Suzuki and Koga 2014, Wirth et al 2018) that despite the widespread clinical use of HbA1c to estimate glycemic control in diabetes mellitus and because of the persistence of high levels of fetal hemoglobin in neonates, HbA1c is not a reliable measure of glycemic control in NDM. We could have measured fructosamine if the diagnosis of diabetes was in doubt and/or performed hemoglobin subtype analysis to correct the HbA1c (Suzuki and Koga 2014), but there was no clinical justification for the additional testing in light of the clinical presentation and significant ketoacidosis.

When it comes to method of insulin delivery, multiple different regimens of subcutaneous insulin therapy by injection were utilized in this case (including different combinations of long-, intermediate-, and short-acting insulin). Early on, a combination of intermediate- and short- acting insulin (with transition to typical basal-bolus regimen later in infancy) was effective in avoiding hypoglycemia and reducing (although certainly not eliminating) glycemic variability; early availability of a continuous glucose sensor was crucial in allowing for frequent adjustments to the patient’s insulin regimen. The successful use of therapy (continuous subcutaneous insulin infusion, CSII) has been well described in cases of NDM (Rubiana-Tufi 2007), even being introduced during initial hospital stay in a case of transient NDM (Park et al 2013). Challenges common to both injection and pump therapy include frequent feedings, limited subcutaneous fat stores, and need for minute doses of insulin in patients with NDM. CSII was discussed with the family and they felt they would prefer to continue with multiple daily injections for the time being, but strong consideration is being given to introducing CSII in the near future, particularly as her size and total daily insulin dose increase.

Downloaded from molecularcasestudies.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press

In summary, we present a case of neonatal diabetes due to a heterozygous de novo INS variant c.26C>G (p.Pro9Arg), a variant affecting the signal peptide of preproinsulin which has not previously been described in cases of NDM due to INS mutations. The development of diabetes in heterozygous INS mutations has been linked to a potential gain-of-toxic-function mechanism as well as to increased ER stress in the setting of (pre)proinsulin misfolding. From the clinical standpoint, this case highlights the utility of genetic testing with rapid turnaround time in therapeutic decision-making. Practical challenges remain in treating our very youngest diabetic patients to achieve glycemic targets without hypoglycemia, which may be mitigated by immediate and widespread availability of continuous glucose sensors to such patients.

Methods: Consent for rapid whole genome sequencing was obtained for the proband and her parents on hospital day 5. Following DNA extraction from whole blood, sequencing libraries were constructed using the TruSeq®DNA PCR-Free Library Prep kit according to the manufacturer’s instructions. Paired-end sequencing (2x100bp) was performed with Illumina chemistry on a Novaseq 6000 to a mean depth of coverage of greater than 40x for the patient and greater than 30x for parental samples (Table 2). The Edico Dragen processor (Illumina, San Diego, CA) was used for rapid alignment and variant calling. Variant analysis and interpretation were performed using the Opal Clinical interface (Fabric Genomics, CA), which employs proprietary algorithms to prioritize candidate variants by integrating phenotypic and genomic data. Variants were filtered to retain those with allele frequencies of <0.5% in multiple population databases including gnomAD, Exome Variant Server, 1000 Genomes, and ExAC. A custom gene panel was then created in Phenolyzer (Yang et al 2015) and used to prioritize review of variants detected in genes known to be associated with hyperglycemia (HPO: 0003074). Manual curation was performed and the c.26C>G (p.Pro9Arg) variant in the INS gene was classified as likely pathogenic (1 strong, 1 moderate, and 1 supporting criteria) according to the ACMG/AMP guidelines for the interpretation of sequence variants (Richards et al 2015). This variant was orthogonally confirmed by Sanger sequencing using the following custom designed forward (F) and reverse (R) primers: F: TTAAAAAAGTGCACCTGACCCCCT and R: TCCAAGGGCCTTTGCGTCAG. Sanger sequencing confirmed the variant was heterozygous in the patient and negative in the parental samples.

Downloaded from molecularcasestudies.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press

Table 2: Sequencing coverage

Trio R18AA922 R18AA923 R18AA924 UNITS Jun 4 Jun 1 Date sample was run 2018 2018 Jun 1 2018 Sex F F (mother) M (father) Yield: raw/bulk 179.5 116.2 125.4 % mapped 98.50% 98.50% 98.20% pct % duplicates 7.90% 7.10% 8.10% pct Yield 176.8 114.4 123.1 Gbp Insert size: Mean 423.6 413.1 407.3 bp Average and median coverage across genome 49.6 32.3 34.3 x Average coverage over OMIM genes 46.7 31.0 32.6 x # of OMIM genes with coverage at <10X 314 703 977 ENST # of OMIM genes with 100% coverage at >=10X 97.8% 95.0% 93.1% pct # of OMIM genes with 100% coverage at >=20X 90.0% 21.2% 35.0% pct # of OMIM genes with 100% coverage at >=30X 37.3% 2.3% 2.7% pct # of genes with 100% coverage at >=40X 4.0% 0.5% 0.9% Variation (VCF) metrics # of calls Total 4,968,231 4,962,138 4,837,935 # of PASS calls 4,887,184 4,903,387 4,775,895 # of calls Total coding 24,742 24,702 24,319 Total # of SNVs 3,969,838 4,008,954 3,897,489 Total # of Indels 917,346 894,433 878,406 Hom/Het ratio (in coding regions) 0.55 0.54 0.60 ratio Ti/Tv ratio (in coding regions) 1.96 1.97 1.97 ratio 3186900 3208560 3007910 # of het calls (# of hom call) (1781331) (1753578) (1830025) units

ADDITIONAL INFORMATION ● Data Deposition and Access Downloaded from molecularcasestudies.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press

The causative variant has been deposited at ClinVar with accession number SCV000898466.1. All data associated with this study are present in the paper or are available at the Longitudinal Pediatric Data Resource under a material transfer agreement or data use agreement, as appropriate, and subject to the limitations of the informed consent documents for each subject (Accession Number nbs000003.v1.p, https://www.nbstrn.org/research-tools/longitudinal- pediatric-data-resource). ● Ethics Statement Written research consent obtained from patient’s parents.Molecular genetic testing was performed under an IRB-approved research protocol with Dr Stephen Kingsmore as the PI: “Prenatal Precision Medicine (NSIGHT2): A Randomized, Blinded, Prospective Study of the Clinical Utility of Rapid Genomic Sequencing for Infants in the Acute-care Setting” ClinicalTrials.gov ID: NCT03211039 ● Acknowledgments We wish to acknowledge the physicians and nurses involved in the patient’s clinical care, and the Rady Children’s Institute of Genomic Medicine. ● Author Contributions S. Laurenzano was the primary author and was involved in the patient’s clinical care. C. McFall, L. Nguyen, and D. Savla were involved in the patient’s clinical care and in writing and review of the manuscript. M. Wright, M. Tokita, D. Dimmock, and S. Kingsmore contributed the genetic testing and interpretation and review of the manuscript. N. Coufal and R. Newfield were involved in the patient’s clinical care and review and editing of the manuscript. ● Funding o Grant U19HD077693 from NICHD and NHGRI

References Babenko AP, Polak M, Cavé H, Busiah K, Czernichow P, Scharfmann R, Bryan J, Aguilar-Bryan L, Vaxillaire M, Froguel P. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med. 2006 Aug 3;355(5):456-66.

Balboa D, Saarimäki-Vire J, Borshagovski D, Survila M, Lindholm P, Galli E, Eurola S, Ustinov J, Grym H, Huopio H, Partanen J, Wartiovaara K, Otonkoski T. Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes. eLife 2018;7:e38519 DOI: 10.7554/eLife.38519

De Franco E, Flanagan SE, Houghton JAL, Allen HL, Mackay DJG, Temple IK, Ellard S, and Hattersley AT. The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study. 2015 The Lancet 386:957-963. https://doi.org/10.1016/S0140-6736(15)60098-8

De León DD, Stanley CA. Permanent Neonatal Diabetes Mellitus. 2008 Feb 8 [Updated 2016 Jul 29]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1447/

Downloaded from molecularcasestudies.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press

Edghill EL, Flanagan SE, Patch AM, Boustred C, Parrish A, Shields B, Shepherd MH, Hussain K, Kapoor RR, Malecki M et al. Insulin mutation screening in 1,044 patients with diabetes: Mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 2008;57:1034–42. Diabetes 2008;57:e9.

Farnaes L, Hildreth A, Sweeney NM, Clark MM, Chowdhury S, Nahas S, Cakici JA, Benson W, Kaplan RH, Kronick R et al. Rapid whole-genome sequencing decreases infant morbidity and cause of hospitalization. NPJ Genom Med. 2018 Apr 4;3:10. doi: 10.1038/s41525-018-0049-4. eCollection 2018.

Iafusco D, Massa O, Pasquino B, the Early Diabetes Study Group of ISPED Minimal incidence of neonatal/infancy onset diabetes in Italy is 1:90,000 live births. Acta Diabetol. 2012;49:405–408.

Konuş OL, Ozdemir A, Akkaya A, Erbaş G, Celik H, Işik S. Normal Liver, Spleen, and Kidney Dimensions in Neonates, Infants, and Children: Evaluation with Sonography. AJR Am J Roentgenol. 1998 Dec;171(6):1693-8.

Liu M, Hodish I, Haataja L, Lara-Lemus R, Rajpal G, Wright J, Arvan P. Proinsulin misfolding and diabetes: Mutant INS gene-induced Diabetes of Youth. Trends Endocrinol Metab. Author manuscript; available in PMC 2011 Nov 1. Published in final edited form as:Trends Endocrinol Metab. 2010 Nov; 21(11): 652–659. Published online 2010 Aug 18. doi: [10.1016/j.tem.2010.07.001]

Liu M, Sun J, Cui J, Chen W, Guo H, Barbetti F, Arvan P. INS-gene mutations: From genetics and biology to clinical disease. Molecular aspects of medicine. 2015;42:3-18. doi:10.1016/j.mam.2014.12.001.

Oyadomari S, Araki E, Mori M. Endoplasmic reticulum stress-mediated apoptosis in pancreatic β-cells. Apoptosis 2002; 7: 335–345.

Park JH, Kang JH, Lee KH, Kim NH, Yoo HW, Lee DY, Yoo EG. Insulin pump therapy in transient neonatal diabetes mellitus. Ann Pediatr Endocrinol Metab. 2013 Sep; 18(3): 148–151. Published online 2013 Sep 30. doi: [10.6065/apem.2013.18.3.148]

Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V et al. Switching from insulin to oral in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006 Aug 3;355(5):467-77.

Polak M, Cave H. Neonatal diabetes mellitus: a disease linked to multiple mechanisms. Orphanet J Rare Dis. 2007;2:12.

Downloaded from molecularcasestudies.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

Rubiana-Tufi N. “Insulin Pump Therapy in Neonatal Diabetes Mellitus.” Shield JPH, Scharfmann R (eds): Development of the and Neonatal Diabetes. Endocr Dev. Basel, Karger, 2007, vol 12, pp 67-74

Støy, Julie. Mutations in the insulin gene [internet]. 2014 Aug 13; Diapedia 4105254815 rev. no. 6. Available from: https://doi.org/10.14496/dia.4105254815.6

Suzuki S and Koga M. Glycemic control indicators in patients with neonatal diabetes mellitus. World J Diabetes. 2014 Apr 15; 5(2): 198–208. Published online 2014 Apr 15. doi: [10.4239/wjd.v5.i2.198]

Wirth M, Jellimann JM, Jellimann S, Hascoët JM. Neonatal diabetes mellitus: improved screening and early management of an underestimated disease. Clin Case Rep. 2018 Jan; 6(1): 18–22. Published online 2017 Nov 20. doi: [10.1002/ccr3.1276]

Yang H, Robinson PN, Wang K. Phenolyzer: phenotype-based prioritization of candidate genes for human diseases. Nat Methods. 2015 Sep;12(9):841-3. doi: 10.1038/nmeth.3484. Epub 2015 Jul 20.

Yildiz M, Akcay T, Aydin B, Akgun A, Dogan BB, De Franco E, Ellard S, Onal H. Emergence of insulin resistance following empirical therapy: a case report of neonatal diabetes with a recessive INS gene mutation. J Pediatr Endocrinol Metab. 2018 Mar 28;31(3):345-348. doi: 10.1515/jpem-2017-0325.

Downloaded from molecularcasestudies.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press

Neonatal Diabetes Mellitus Due to a Novel Variant in the INS Gene

Sarah E. Laurenzano, Cory McFall, Linda Nguyen, et al.

Cold Spring Harb Mol Case Stud published online June 13, 2019 Access the most recent version at doi:10.1101/mcs.a004085

Published online June 13, 2019 in advance of the full issue.

Accepted Peer-reviewed and accepted for publication but not copyedited or typeset; accepted Manuscript manuscript is likely to differ from the final, published version. Published onlineJune 13, 2019in advance of the full issue.

Creative This article is distributed under the terms of the Commons http://creativecommons.org/licenses/by-nc/4.0/, which permits reuse and License redistribution, except for commercial purposes, provided that the original author and source are credited. Email Alerting Receive free email alerts when new articles cite this article - sign up in the box at the Service top right corner of the article or click here.

Published by Cold Spring Harbor Laboratory Press